PolypharmacyLIMONCELLONCT05899114
Less Is More: Optimized Pharmacotherapy With Improved coNtinuity of CarE in hospitaLized oLder peOple
A study testing Transitional Multidisciplinary Pharmacotherapeutic Care in people with Polypharmacy and Medication Review, run by Radboud University Medical Center at 16 sites in Netherlands.
Trial summary
The goal of this cluster randomized controlled trial is to compare transitional multidisciplinary pharmacotherapeutic care (TMPC) with usual care in patients aged 70 years or older with polypharmacy, admitted to the hospital via the emergency department for longer than 24 hours and that have an elevated risk of drug… Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Polypharmacy, Medication Review
- What is being tested?
- Transitional Multidisciplinary Pharmacotherapeutic Care
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,241 participants
- Where
- 16 sitesNetherlands
- Study dates
- 5 Jun 2023to 17 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- 70 years or older
- Polypharmacy, the use of 5 or more regular medications, defined as authorised medications with registration numbers, used for more than 30 days. Topical preparations are excluded from this definition.
- Admitted to hospital through the ED (which comprises both the general emergency department and the cardiac emergency department)
- Length of hospitalisation more than 24 hours
- Completed medication verification
- DRA prediction percentage of 23.0% or higher
Who cannot join
- No informed consent by patient or a legal representative
- Participation in an interfering clinical trial
- Elective hospital admission
- Direct admission to the ICU (when medication verification as usual can't be executed, and therefore inclusion of patients as described in 10.2 is not possible)
- A life expectancy of less than 3 months, which includes patients with palliative treatment at home, direct admission to palliative care or palliative care planned within 24 hours after index hospital admission.
- Patient or legal representative not able to speak Dutch.
Show all 11Show fewer
- Follow-up of patient primarily by secondary caregivers. This refers to situations where the secondary caregiver is in the lead of the medication list of the patient instead of the GP or elderly care physician, for example in the following patient groups:
- patients receiving intensive oncologic therapy
- patients in an organ- or stem cell transplantation procedure
- patients receiving intensive (chronic) psychiatric care, such as patients admitted to a medical psychiatric unit
- patients on dialysis
Trial locations and contacts
16 sites in 1 country.
16 sites in 1 country
Netherlands16 sites
Ziekenhuisgroep Twente
Almelo, Overijssel
Meander Medisch Centrum Amersfoort
Amersfoort, Utrecht
Amsterdam UMC - location VUMC
Amsterdam, North Holland
Amsterdam UMC- location AMC
Amsterdam, North Holland
Amphia ziekenhuis
Breda, North Brabant
Deventer Ziekenhuis
Deventer, Overijssel
Catharina Ziekenhuis
Eindhoven, North Brabant
Universitair Medisch Centrum Groningen
Groningen, Provincie Groningen
Leiden Universitair Medisch Centrum
Leiden, South Holland
Canisius Wilhelmina Ziekenhuis
Nijmegen, Gelderland
Radboudumc
Nijmegen, Gelderland
Erasmus Medisch Centrum Rotterdam
Rotterdam, South Holland
Haga Ziekenhuis
The Hague, South Holland
Diakonessenhuis
Utrecht, Utrecht
Universitair Medisch Centrum Utrecht
Utrecht, Utrecht
Zaans Medisch Centrum
Zaandam, North Holland
About this study
The goal of this cluster randomized controlled trial is to compare transitional multidisciplinary pharmacotherapeutic care (TMPC) with usual care in patients aged 70 years or older with polypharmacy, admitted to the hospital via the emergency department for longer than 24 hours and that have an elevated risk of drug related readmissions.
The primary aims of the study are:
Read more
- To assess whether TMPC leads to a decrease in number of DRreAs compared to usual care during the first 30 days after index hospitalisation.
- To assess whether TMPC is cost-effective
Participants will receive TMPC in hospitals allocated to the intervention. TMPC will be executed by a pharmacotherapeutic team, it consists of the following four elements:
- pharmacotherapeutic analysis
- transitional multidisciplinary discussion
- pharmacotherapeutic care interview and discussion with the patient
- discharge note with the pharmacotherapeutic care plan
Researchers will compare TMPC with usual care to assess the effect and cost-effectiveness of TMPC.
Read the detailed description
Rationale: Polypharmacy poses an ongoing healthcare challenge, as it is associated with negative outcomes such as adverse drug events, lower quality of life and mortality. These risks are especially elevated for the frail and old, leading to high numbers of drug related admissions (DRAs) and unplanned emergency department visits. Approximately half of the DRAs are potentially preventable, and therefore a possible target point for interventions. Unfortunately, until now, despite multiple efforts to decrease drug related harm, the number of drug related admissions has not decreased. Several studies have previously investigated the effect of a structured medication review with varying success. Identified strengths were multicomponent approaches, multidisciplinary approaches and selection of specifically high-risk patients. The LIMONCELLO study will take this into account and will study a multidisciplinary multicomponent intervention with focus on transitional care in a patient population that is most likely to benefit from this intervention. It is hypothesised that transitional multidisciplinary pharmacotherapeutic care (TMPC) is superior in preventing drug related readmissions (DRreAs) compared to usual care.
Objective: The LIMONCELLO study aims to assess the effect and cost-effectiveness of TMPC compared to usual care.
Study design: This is a cluster randomised controlled trial, a cluster will be defined at the hospital level, with each cluster randomly allocated to the intervention or control group. Patients aged 70 years or older with polypharmacy, admitted to the hospital via the emergency department for longer than 24 hours, with completed medication verification and with an elevated risk of drug related readmissions (calculated by use of the DRA prediction model, an algorithm developed by the OPERAM study group) will be included. Participants in intervention hospitals will receive TMPC during index hospitalisation. TMPC consists of four elements: pharmacotherapeutic analysis, transitional multidisciplinary discussion, pharmacotherapeutic care interview and discussion with the patient, and a discharge note with the pharmacotherapeutic care plan. The comparator is usual care as is provided in the participating hospitals. Follow-up will be 1 year, participants will be called 30 days, 3 months and 12 months after index hospitalisation.
Statistical considerations: 16 clusters will participate in the study, requiring a total of 161 patients per cluster to be included, 2,576 participants in total. Results will be analysed by intention-to-treat analysis and per-protocol analysis. For the primary outcome, drug related readmissions, a generalized linear mixed model with a binomial distribution and logit link function will be used for the analysis on an individual level, adjusting for clustering.
- Conditions
- Polypharmacy, Medication Review
- Being tested
- Transitional Multidisciplinary Pharmacotherapeutic Care
- Keywords
- Polypharmacy, Medication Review, Aged, Deprescribing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transitional Multidisciplinary Pharmacotherapeutic CareOther
Also called TMPC
A structured medication review with improved transitional care and multidisciplinary collaboration.
TMPC consists of the following four elements:
- A structured pharmacotherapeutic analysis
- A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.
- An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.
- A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner.
| Study group | Role | What they receive |
|---|---|---|
| Transitional Multidisciplinary Pharmacotherapeutic Care (TMPC) | Experimental | The participants in hospitals allocated to the intervention arm will receive TMPC, which will be executed by a Pharmacotherapy-team and will take place during the index hospital stay. This Pharmacotherapy-team will be composed of a physician and a hospital pharmacist, preferably registered as clinical pharmacologists. Receives: Other: Transitional Multidisciplinary Pharmacotherapeutic Care |
| Usual care | No intervention | The comparator in this study is usual care, which refers to the entire spectrum of medication-related interventions by different healthcare providers (physician, pharmacist, nurse etc.) which the patient undergoes during hospital admission. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Drug Related Readmissions in the first 30 days after index hospitalisation
Whether readmission is drug related will be assessed with AT-HARM10
Measured: 30 days after index hospitalisation
Secondary outcomes (15)
Number of Drug Related Readmissions at 3 and 12 months after index hospitalisation
Whether readmission is drug related will be assessed with AT-HARM10
Measured: 3 and 12 months after index hospitalisation
Duration of hospitalisation of Drug Related Readmission
Whether readmission is drug related will be assessed with AT-HARM10
Measured: 30 days, 3 months and 12 months after index hospitalisation
Time to first Drug Related Readmission
Whether readmission is drug related will be assessed with AT-HARM10
Measured: 30 days, 3 months and 12 months after index hospitalisation
Number of Emergency Department visits
Measured: 30 days, 3 months and 12 months after index hospitalisation
Number of all-cause hospital readmissions
Measured: 30 days, 3 months and 12 months after index hospitalisation
Healthcare costs
In euros, assessed with the iMTA Medical Consumption Questionnaire (iMCQ)
Measured: 30 days, 3 months and 12 months after index hospitalisation
Quality of Life measured with EQ-5D-5L
Measured by 5-level EuroQol-5 domains (EQ-5D-5L) questionnaire
Measured: 30 days, 3 months and 12 months after index hospitalisation
Cost-effectiveness
In euro per Quality Adjusted Life Year (QALY) gained, by combining costs and quality of life measurements
Measured: During the 12 month follow-up
Number of regular medications
Based on number of regular medications in the medication list
Measured: At discharge from index hospitalisation and 30 days, 3 months and 12 months after index hospitalisation
Number and type of recommendations in the intervention group
Based on documented recommendations made during TMPC
Measured: At discharge from index hospitalisation
Number of implemented recommendations
The number of differences between the pharmacotherapeutic plan composed by the P-team and the participant's current medication list at each time point
Measured: 30 days, 3 months and 12 months after index hospitalisation
Activities of Daily Living
Measured with Katz-6 ADL questionnaire
Measured: 30 days, 3 months and 12 months after index hospitalisation
Number of patients living independently
Measured: 30 days, 3 months and 12 months after index hospitalisation
Number of falls
Measured: 30 days, 3 months and 12 months after index hospitalisation
Mortality
Measured: 30 days, 3 months and 12 months after index hospitalisation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2023
- Study start5 Jun 2023
- Primary completion1 Apr 2025
- Study completion17 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PolypharmacyStudies of the same condition, open and under way.
- More trials run by Radboud University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Cluster randomized study
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,241 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radboud University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Amsterdam UMC, location VUmc, Amsterdam UMC, location AMC, Amphia ziekenhuis, Catharina Ziekenhuis Eindhoven, Deventer Ziekenhuis, Diakonessenhuis, Utrecht, Erasmus Medical Center, HagaZiekenhuis, Leiden University Medical Center, Meander Medisch Centrum, University Medical Center Groningen, UMC Utrecht, Zaans Medisch Centrum, Ziekenhuisgroep Twente, ZonMw: The Netherlands Organisation for Health Research and Development, Zorgevaluatie Nederland, Canisius-Wilhelmina Hospital
- Responsible party
- Sponsor
- Investigators
- Kees Kramers, Prof. Dr., Principal investigator, Radboud University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05899114
- Sponsor's protocol ID
- NL82393.091.22
- Other IDs
- 10330032010002
- Acronym
- LIMONCELLO
- Status last verified
- Jun 2026
- First submitted
- 23 May 2023
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized data will be shared in a repository, published under restricted access.
Publications
Cooijmans S, Engelen EMC, Wuyts SCM, Kramers C, van Agtmael MA, van den Bemt PMLA, Bouvy ML, Amouch H, Autar RS, Benoist GE, van Berlo-van de Laar IRF, Derijks-Engwegen JYMN, van den Elsen G, Engelaer FM, Gombert-Handoko KB, Jansen DRM, Kerskes MHM, Kruik-Kolloffel WJ, Kuijvenhoven MA, van der Kuy HM, Labots G, van Poelgeest EP, Sablerolles R, Sallevelt BTG, van Stiphout F, Storm BN, Taks M, Teeuwisse PJI, Uiterwijk J, Vondeling A, de Vries M, Wesselink E, Wiggers NML, de Wit HAJM, Schers HJ, Adang EMM, van Wely M, van Herwaarden N, Knol W. Less Is More: Optimized pharmacotherapy with improved coNtinuity of CarE in hospitaLized oLder peOple (LIMONCELLO): study protocol of a cluster randomized controlled trial. BMC Geriatr. 2025 Dec 24;25(1):1034. doi: 10.1186/s12877-025-06533-0.
PubMed 41444867
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Less Is More: Optimized Pharmacotherapy With Improved coNtinuity of CarE in hospitaLized oLder peOple
- ClinicalTrials.gov ID
- NCT05899114
- Acronym / sponsor ID
- LIMONCELLO / NL82393.091.22
- Conditions
- Polypharmacy, Medication Review
- Keywords
- Polypharmacy, Medication Review, Aged, Deprescribing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,241 participants (actual)
- Lead sponsor
- Radboud University Medical CenterUniversity, hospital or other
- Collaborators
- Amsterdam UMC, location VUmc, Amsterdam UMC, location AMC, Amphia ziekenhuis, Catharina Ziekenhuis Eindhoven, Deventer Ziekenhuis, Diakonessenhuis, Utrecht, Erasmus Medical Center, HagaZiekenhuis, Leiden University Medical Center, Meander Medisch Centrum, University Medical Center Groningen, UMC Utrecht, Zaans Medisch Centrum, Ziekenhuisgroep Twente, ZonMw: The Netherlands Organisation for Health Research and Development, Zorgevaluatie Nederland, Canisius-Wilhelmina Hospital
- Study start
- 5 Jun 2023 (actual)
- Primary completion
- 1 Apr 2025 (actual)
- Study completion
- 17 Feb 2026 (actual)
- First posted
- 12 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this cluster randomized controlled trial is to compare transitional multidisciplinary pharmacotherapeutic care (TMPC) with usual care in patients aged 70 years or older with polypharmacy, admitted to the hospital via the emergency department for longer than 24 hours and that have an elevated risk of drug related readmissions.
The primary aims of the study are:
- To assess whether TMPC leads to a decrease in number of DRreAs compared to usual care during the first 30 days after index hospitalisation.
- To assess whether TMPC is cost-effective
Participants will receive TMPC in hospitals allocated to the intervention. TMPC will be executed by a pharmacotherapeutic team, it consists of the following four elements:
- pharmacotherapeutic analysis
- transitional multidisciplinary discussion
- pharmacotherapeutic care interview and discussion with the patient
- discharge note with the pharmacotherapeutic care plan
Researchers will compare TMPC with usual care to assess the effect and cost-effectiveness of TMPC.
Detailed description
Rationale: Polypharmacy poses an ongoing healthcare challenge, as it is associated with negative outcomes such as adverse drug events, lower quality of life and mortality. These risks are especially elevated for the frail and old, leading to high numbers of drug related admissions (DRAs) and unplanned emergency department visits. Approximately half of the DRAs are potentially preventable, and therefore a possible target point for interventions. Unfortunately, until now, despite multiple efforts to decrease drug related harm, the number of drug related admissions has not decreased. Several studies have previously investigated the effect of a structured medication review with varying success. Identified strengths were multicomponent approaches, multidisciplinary approaches and selection of specifically high-risk patients. The LIMONCELLO study will take this into account and will study a multidisciplinary multicomponent intervention with focus on transitional care in a patient population that is most likely to benefit from this intervention. It is hypothesised that transitional multidisciplinary pharmacotherapeutic care (TMPC) is superior in preventing drug related readmissions (DRreAs) compared to usual care.
Objective: The LIMONCELLO study aims to assess the effect and cost-effectiveness of TMPC compared to usual care.
Study design: This is a cluster randomised controlled trial, a cluster will be defined at the hospital level, with each cluster randomly allocated to the intervention or control group. Patients aged 70 years or older with polypharmacy, admitted to the hospital via the emergency department for longer than 24 hours, with completed medication verification and with an elevated risk of drug related readmissions (calculated by use of the DRA prediction model, an algorithm developed by the OPERAM study group) will be included. Participants in intervention hospitals will receive TMPC during index hospitalisation. TMPC consists of four elements: pharmacotherapeutic analysis, transitional multidisciplinary discussion, pharmacotherapeutic care interview and discussion with the patient, and a discharge note with the pharmacotherapeutic care plan. The comparator is usual care as is provided in the participating hospitals. Follow-up will be 1 year, participants will be called 30 days, 3 months and 12 months after index hospitalisation.
Statistical considerations: 16 clusters will participate in the study, requiring a total of 161 patients per cluster to be included, 2,576 participants in total. Results will be analysed by intention-to-treat analysis and per-protocol analysis. For the primary outcome, drug related readmissions, a generalized linear mixed model with a binomial distribution and logit link function will be used for the analysis on an individual level, adjusting for clustering.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Cluster randomized study
| Arm | Type | Receives |
|---|---|---|
| Transitional Multidisciplinary Pharmacotherapeutic Care (TMPC) | Experimental | Other: Transitional Multidisciplinary Pharmacotherapeutic CareThe participants in hospitals allocated to the intervention arm will receive TMPC, which will be executed by a Pharmacotherapy-team and will take place during the index hospital stay. This Pharmacotherapy-team will be composed of a physician and a hospital pharmacist, preferably registered as clinical pharmacologists. |
| Usual care | No intervention | –The comparator in this study is usual care, which refers to the entire spectrum of medication-related interventions by different healthcare providers (physician, pharmacist, nurse etc.) which the patient undergoes during hospital admission. |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (6 listed)
- 70 years or older
- Polypharmacy, the use of 5 or more regular medications, defined as authorised medications with registration numbers, used for more than 30 days. Topical preparations are excluded from this definition.
- Admitted to hospital through the ED (which comprises both the general emergency department and the cardiac emergency department)
- Length of hospitalisation more than 24 hours
- Completed medication verification
Key exclusion criteria (11 listed)
- No informed consent by patient or a legal representative
- Participation in an interfering clinical trial
- Elective hospital admission
- Direct admission to the ICU (when medication verification as usual can't be executed, and therefore inclusion of patients as described in 10.2 is not possible)
- A life expectancy of less than 3 months, which includes patients with palliative treatment at home, direct admission to palliative care or palliative care planned within 24 hours after index hospital admission.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transitional Multidisciplinary Pharmacotherapeutic CareAlso: TMPCA structured medication review with improved transitional care and multidisciplinary collaboration. TMPC consists of the following four elements: 1. A structured pharmacotherapeutic analysis 2. A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted. 3. An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital. 4. A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner. | Other | Transitional Multidisciplinary Pharmacotherapeutic Care (TMPC) |
Primary outcome
Number of Drug Related Readmissions in the first 30 days after index hospitalisation
Time frame: 30 days after index hospitalisation
Whether readmission is drug related will be assessed with AT-HARM10
15 secondary outcomes
Number of Drug Related Readmissions at 3 and 12 months after index hospitalisation
Time frame: 3 and 12 months after index hospitalisation
Duration of hospitalisation of Drug Related Readmission
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Time to first Drug Related Readmission
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Number of Emergency Department visits
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Number of all-cause hospital readmissions
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Healthcare costs
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Quality of Life measured with EQ-5D-5L
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Cost-effectiveness
Time frame: During the 12 month follow-up
Number of regular medications
Time frame: At discharge from index hospitalisation and 30 days, 3 months and 12 months after index hospitalisation
Number and type of recommendations in the intervention group
Time frame: At discharge from index hospitalisation
Number of implemented recommendations
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Activities of Daily Living
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Number of patients living independently
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Number of falls
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Mortality
Time frame: 30 days, 3 months and 12 months after index hospitalisation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Background: PubMed 41444867Cooijmans S, Engelen EMC, Wuyts SCM, Kramers C, van Agtmael MA, van den Bemt PMLA, Bouvy ML, Amouch H, Autar RS, Benoist GE, van Berlo-van de Laar IRF, Derijks-Engwegen JYMN, van den Elsen G, Engelaer FM, Gombert-Handoko KB, Jansen DRM, Kerskes MHM, Kruik-Kolloffel WJ, Kuijvenhoven MA, van der Kuy HM, Labots G, van Poelgeest EP, Sablerolles R, Sallevelt BTG, van Stiphout F, Storm BN, Taks M, Teeuwisse PJI, Uiterwijk J, Vondeling A, de Vries M, Wesselink E, Wiggers NML, de Wit HAJM, Schers HJ, Adang EMM, van Wely M, van Herwaarden N, Knol W. Less Is More: Optimized pharmacotherapy with improved coNtinuity of CarE in hospitaLized oLder peOple (LIMONCELLO): study protocol of a cluster randomized controlled trial. BMC Geriatr. 2025 Dec 24;25(1):1034. doi: 10.1186/s12877-025-06533-0.
- LIMONCELLO website in collaboration with "Zorgevaluatie Nederland"Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized data will be shared in a repository, published under restricted access.
Related trials for Polypharmacy
Not yet recruiting
Impact of Pharmacotherapy Optimization in Polymedicated Lebanese Older Adults in Primary Health Care Centers
Older Adults (65 Years and Older), Polypharmacy (People Under Treatment With 5 or More Drugs)
Active, not recruiting
Optimizing Prescribing Decisions for Hospitalized Older Adults With Chronic Conditions
Prescribing Decisions, Diabetes
Recruiting
Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75
Virus-HIV
Active, not recruiting
Improving Medication Management in World Trade Center Responders
Polypharmacy
Recruiting
PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)
Pharmacogenomic Drug Interaction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kees Kramers, Prof. Dr. principal investigator
Radboud University Medical Center
16 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transitional Multidisciplinary Pharmacotherapeutic Care in people with Polypharmacy and Medication Review, run by Radboud University Medical Center at 16 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Drug Related Readmissions in the first 30 days after index hospitalisation (time frame: 30 days after index hospitalisation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05899114, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.